financetom
Business
financetom
/
Business
/
KB Home Q4 Earnings: Revenue Beat, EPS Beat, Home Deliveries Up 17%, Net Orders Soar And More
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KB Home Q4 Earnings: Revenue Beat, EPS Beat, Home Deliveries Up 17%, Net Orders Soar And More
Jan 13, 2025 2:13 PM

KB Home ( KBH ) reported financial results for the fourth quarter after the market close on Monday. Here’s a rundown of the report.

Q4 Earnings: KB Home ( KBH ) reported fourth-quarter revenue of $2 billion, beating analyst estimates of $1.99 billion. The U.S. homebuilder reported fourth-quarter earnings of $2.52 per share, beating analyst estimates of $2.39 per share, according to Benzinga Pro.

Total revenue was up 19% year-over-year. KB Home ( KBH ) delivered 3,978 homes in the quarter, up 17% year-over-year. Average selling price was $501,000, up 3%, and net orders climbed 41% year-over-year to 2,688.

“Our higher revenues reflected an increase in deliveries, which were driven by faster build times. Net orders rose roughly 40% year over year, as buyers continued to demonstrate a desire for homeownership and housing market conditions improved relative to last year, despite ongoing mortgage interest rate headwinds,” said Jeffrey Mezger, chairman and CEO of KB Home ( KBH ).

“In 2025, we will remain focused on expanding our scale, profitability and returns. We believe we are poised for growth having invested over $2.8 billion in land acquisition and development in 2024, and we plan to increase our investment again in 2025.”

KB Home ( KBH ) said it repurchased $100 million worth of its common stock during the quarter. The company had $700 million remaining under its buyback program as of Nov. 30.

Guidance: KB Home ( KBH ) expects full-year 2025 housing revenue to be in the range of $7 billion to $7.5 billion. The company anticipates 2025 average selling prices of $488,000 to $498,000.

KB Home ( KBH ) noted that it will provide guidance for the first quarter on its conference call, which is scheduled for 5 p.m. ET.

KBH Price Action: KB Home ( KBH ) shares were up 8% at $69.24 at the time of publication Monday, according to Benzinga Pro.

Read Next:

What’s Going On With United States Steel Shares Monday?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Mar 11, 2026
08:13 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that the Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. The ongoing pivotal Phase 3 study is being conducted...
Palo Alto Networks Announces Intent to Acquire Koi to Secure the Agentic Endpoint
Palo Alto Networks Announces Intent to Acquire Koi to Secure the Agentic Endpoint
Mar 11, 2026
Eliminates the AI security gap by establishing Agentic Endpoint Security as the next frontier of enterprise risk reduction SANTA CLARA, Calif., Feb. 17, 2026 /PRNewswire/ -- As AI transforms workforce productivity, it has created a dangerous, unmanaged attack surface on every endpoint. These AI agents and tools—the Agentic Endpoint—operate with deep access to sensitive data, unrestricted permissions, and the ability...
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data. The company said the board, which neets quarterly in accordance...
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- Pfizer ( PFE ) on Tuesday reported positive results from a trial evaluating Braftovi in combination with cetuximab and Folfiri in patients with previously untreated metastatic colorectal cancer. The regimen showed a statistically significant and clinically meaningful improvement in progression-free survival, a key secondary endpoint, Pfizer ( PFE ) said. Overall survival, a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved